Featured Research

from universities, journals, and other organizations

Historic Gene Therapy Trial To Treat Alzheimer's Disease

Date:
September 23, 2009
Source:
Georgetown University Medical Center
Summary:
Researchers are now recruiting volunteers for a national gene therapy trial -- the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.

Researchers in the Memory Disorders Program at Georgetown University Medical Center are now recruiting volunteers for a national gene therapy trial – the first study of its kind for the treatment of patients with dementia due to Alzheimer's disease.

The phase II study examines the safety and possible benefits of CERE-110. CERE-110 contains a gene and is injected during surgery into a part of the brain affected by Alzheimer's disease. The gene will instruct brain cells to produce more of a protein, called Nerve Growth Factor or NGF, which helps nerve cells survive and function properly. The transfer of this gene into the brain is a medical technique called gene therapy.

"Our goal is to stop the progression of Alzheimer's disease," explains R. Scott Turner, MD, PhD, director of Georgetown's Memory Disorders Program. "This is our first study of a gene therapy injected into brain, and thus the trial requires close collaboration with our neurosurgery colleagues at GUMC, in particular Dr. Chris Kalhorn."

Turner says Kalhorn, an associate professor of the department of neurosurgery at Georgetown University Hospital, routinely performs neurosurgical procedures similar to the one being utilized in this study.

About 50 people with Alzheimer's disease will participate in this study at fewer than 10 hospitals nationwide. Only persons with a mild form of Alzheimer's Disease, who are evaluated and deemed competent to consent for themselves, will be permitted to participate in the study. The study requires each patient select a study partner for the length of the study. All patients in the study will undergo surgery to drill two small holes in the skull. Only those patients randomly assigned to receive CERE-110 will have the gene therapy injected into the brain. Those subjects randomized to the placebo group will not have the gene therapy injected.

This study is a phase II, double-blind, placebo-controlled study.

Phase II means the investigational agent has been studied in a small number of patients and this study is being conducted to determine its safety and possible benefits.

Double-blind means that the patients, clinical coordinators and treating physicians will not know if the patient received the investigational agent until the end of the study. Only the neurosurgeon and operating team delivering the gene therapy will know if the patient received the active agent.

Placebo–controlled means that patients will be selected randomly to either receive the active agent or not, but all patients will undergo surgery. This study has been approved by the FDA and the Institutional Review Board at GUMC.

This study is sponsored by the Alzheimer's Disease Cooperative Study (ADCS) through a grant from the National Institute on Aging (a part of the NIH) in association with Ceregene, Inc, which will provide the active agent used in this study. GUMC will be reimbursed for the costs of performing the study by the ADCS. Turner, the study's lead investigator at Georgetown, has no financial interests to disclose.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Historic Gene Therapy Trial To Treat Alzheimer's Disease." ScienceDaily. ScienceDaily, 23 September 2009. <www.sciencedaily.com/releases/2009/09/090922132848.htm>.
Georgetown University Medical Center. (2009, September 23). Historic Gene Therapy Trial To Treat Alzheimer's Disease. ScienceDaily. Retrieved April 20, 2014 from www.sciencedaily.com/releases/2009/09/090922132848.htm
Georgetown University Medical Center. "Historic Gene Therapy Trial To Treat Alzheimer's Disease." ScienceDaily. www.sciencedaily.com/releases/2009/09/090922132848.htm (accessed April 20, 2014).

Share This



More Health & Medicine News

Sunday, April 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Nine-Month-Old Baby Can't Open His Mouth

Nine-Month-Old Baby Can't Open His Mouth

Newsy (Apr. 19, 2014) Nine-month-old Wyatt Scott was born with a rare disorder called congenital trismus, which prevents him from opening his mouth. Video provided by Newsy
Powered by NewsLook.com
'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins